Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00474279 · ClinicalTrials.gov registry record · Phase 1

Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults

A Phase 1 study, sponsored by University of Virginia.

Completed
Registry status
Phase 1
Development phase
72
Enrollment target

NCT00474279 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 72 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00474279, a Phase 1 study, has completed, sponsored by University of Virginia.

COMPLETED
Registry status
Phase 1
Development phase
72 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether treatment of healthy older men and women with oral MK-677 for 12 months will enhance pulsatile GH release and increase mean GH and IGF-I concentrations into the range of young adults and will have favorable effects on body composition and functional ability on older adults.

Interventions

  • DRUG Orally active growth hormone secretagogue (MK-677)

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 1998-07
Est. Completion 2004-06
Phase Phase 1

Sponsor

University of Virginia

449 total trials

What the Registry Record Tells You About NCT00474279

The ClinicalTrials.gov registry entry for NCT00474279 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Orally active growth hormone secretagogue (MK-677) is the first listed.

NCT00474279 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00474279 about?

NCT00474279 is a clinical study titled "Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults". The purpose of this study is to determine whether treatment of healthy older men and women with oral MK-677 for 12 months will enhance pulsatile GH release and increase mean GH and IGF-I concentrations into the range of young adults and will have favorable effects on body composition and functional ...

What is the current status of trial NCT00474279?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 1998-07. Estimated completion is 2004-06.

What interventions are being tested in trial NCT00474279?

The interventions under investigation include: Orally active growth hormone secretagogue (MK-677) (DRUG).

Who is sponsoring clinical trial NCT00474279?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.